New Advances and Challenges for Radiotherapy of Gastrointestinal Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 145
Special Issue Editor
Special Issue Information
Dear Colleagues,
Gastrointestinal (GI) tumors are leading cause of cancer-related mortality and remain a big challenge for cancer treatment. The role of radiotherapy in multidisciplinary treatment of GI malignancies is well recognized, also in curative treatment of elderly patients. Advances in imaging, radiotherapy planning and delivery techniques as well as the integration with novel drugs have made it possible to improve clinical oncological outcomes with better quality of life, less adverse events and more organ reserving strategies. The role of intensity-modulated radiotherapy and stereotactic body radiotherapy is grown for many GI malignancies. Modern imaging techniques, in particular, magnetic resonance imaging and positron emission tomography scans have been progressively used in radiotherapy planning and to assess treatment response. Moreover, integrated MRI-linear accelerator systems (MR-linacs) can adapt the treatment based on daily changes in shape, size and position of the tumor and surrounding tissue and to increase the accuracy of treatment delivery. Finally, molecular biomarkers and radiomics have been investigated as predictors of prognosis and response to radiotherapy. Despite these advances a fair number of patients still develop distant metastases and therapy resistance, and new therapeutic strategies are then now required to improve the prognosis of GI cancers. The current issue aims to increase our knowledge to achieve these goals.
We are pleased to invite you for both original research and review articles that highlight recent advances in the followed (but are not limited to) fields of research in gastrointestinal cancer:
1. Advances in the curative multimodal management.
2. Treatment options for elderly patients.
3. Organ preservation strategies and “watch and wait” approach.
4. Integration of Immunotherapy and Target therapies with radiotherapy.
5. The role of MRI in radiotherapy: from staging to delivery and response evaluation and prediction.
We look forward to receiving your contributions.
Dr. Luciana Caravatta
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gastrointestinal cancer
- esophageal cancer
- pancreatic cancer
- colorectal cancer
- anal cancer
- biomarkers
- magnetic resonance imaging
- radiomics
- immunotherapy
- particle therapy
